Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 71.26M | 36.64M | 5.62M | -- | -- |
| Total Other Revenue | 5.00M | 18.00K | -- | -- | -- |
| Total Revenue | 76.26M | 36.66M | 5.62M | -- | -- |
| Cost of Revenue | 3.41M | 2.04M | 543.00K | -- | -- |
| Gross Profit | 72.85M | 34.62M | 5.08M | -- | -- |
| SG&A Expenses | 69.11M | 45.09M | 35.20M | 49.04M | 20.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.57M | 54.44M | 44.68M | 67.58M | 26.61M |
| Operating Income | -10.32M | -17.78M | -39.06M | -67.58M | -26.61M |
| Income Before Tax | -16.56M | -25.56M | -42.71M | -69.82M | -25.04M |
| Income Tax Expenses | -239.00K | 8.27M | 250.00K | 1.01M | 754.00K |
| Earnings from Continuing Operations | -16.32M | -33.83M | -42.96M | -70.84M | -25.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.32M | -33.83M | -42.96M | -70.84M | -25.79M |
| EBIT | -10.32M | -17.78M | -39.06M | -67.58M | -26.61M |
| EBITDA | -10.02M | -17.52M | -38.79M | -67.31M | -26.35M |
| EPS Basic | -1.54 | -3.26 | -4.22 | -6.99 | -2.56 |
| Normalized Basic EPS | -0.12 | -0.19 | -0.33 | -0.51 | -0.19 |
| EPS Diluted | -1.54 | -3.52 | -4.22 | -6.99 | -2.56 |
| Normalized Diluted EPS | -0.12 | -0.19 | -0.33 | -0.51 | -0.19 |
| Average Basic Shares Outstanding | 84.93M | 82.91M | 81.49M | 81.03M | 80.71M |
| Average Diluted Shares Outstanding | 10.62M | 10.36M | 10.19M | 10.13M | 10.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |